Trials of bluebird's LentiGlobin now on FDA hold

25 February 2021
bluebird_bio_large

The US Food and Drug Administration (FDA) has placed bluebird bio’s (Nasdaq: BLUE) Phase I/II and Phase III studies of LentiGlobin gene therapy for sickle cell disease (SCD) on a clinical hold.

This action from the FDA comes after the US biotech voluntarily suspended the studies temporarily following a reported suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukemia (AML), news that sent bluebird's share price to drop 38% lower in a single day last week.

In line with the clinical study protocols for the trial, bluebird bio had placed the studies on temporary suspension following a report received earlier this month that a patient who was treated more than five years ago in the Phase I/II study was diagnosed with AML.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology